PR Newswire BiotechnologyQwen · 实盘不做把握 1/10不做原因:不是事件🔁 +2 同一事件
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:00:32 +32s·⚡ 决策 08-26 19:39:29 +38m57s·61.9 天前
Insmed宣布管理层将于9月参加Cantor Fitzgerald和Morgan Stanley投资者会议
该公告仅通知管理层将出席两场投资者会议，属于上市公司最常规的IR日程安排，不含任何关于管线、临床、监管、业绩或商业化的新增事实，无法构成任何方向性交易催化。
📄 原文PR Newswire Biotechnology↗ 原文
Insmed to Present at September 2026 Investor Conferences
BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceu…
不做 Insmed Incorporated（INSM.US）
纯IR日程公告，不含任何新业务/临床/监管/财务信息，无方向性催化，无交易edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Insmed通过PR Newswire发布投资者会议出席公告，内容为9月9日Cantor Fitzgerald会议和9月14日Morgan Stanley会议的演讲安排。公告不包含任何新临床数据、FDA进展、业绩指引、合作或订单信息，属于纯程序性IR活动，对股价无增量信息，不构成可交易催化。
🔎 新鲜度:最早出现 2026-08-26 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无
方向:无先例可用，事件本身无方向性
涨幅量级:不适用
形态:不适用
工具调用 · 历史记录,结果未知(1 种)
- fetch_decision_experience · 结果未知
原文全文
展开原文 · 2,283 字
BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:
- 12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET.
- 24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET.
These events will be webcasted live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.
Contact:
Investors:
Sara Bonstein
Chief Financial Officer
[email protected]
Media:
Claire Mulhearn
Vice President, Corporate Communications
[email protected]
SOURCE Insmed Incorporated
- 12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET.
- 24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET.
These events will be webcasted live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.
Contact:
Investors:
Sara Bonstein
Chief Financial Officer
[email protected]
Media:
Claire Mulhearn
Vice President, Corporate Communications
[email protected]
SOURCE Insmed Incorporated
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。